CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that preclinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company’s monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.
